Gracey Craig sold $40K of OMDA

Gracey Craig (Chief Accounting Officer) sold 2,083 shares of Omada Health, Inc. (OMDA) at $19.01 on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Jun 26, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
medium confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure updates the insider’s post-transaction holdings (5,025 shares) but does not indicate a change in company fundamentals or guidance.

02

Market read

Traders may monitor insider activity, but this specific transaction is likely low-signal due to the 10b5-1 structure and modest size.

03

What to watch

The filing date is later than the trade date; any short-term sentiment impact should be weighed against the fact the sale already occurred on 6/24.

Relevance 2/10Novelty 5/10Timing: filed 2026-06-26 after-hours; sale executed 2026-06-24

Background

SEC Form 4 reports an officer’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$OMDANeutralMedium confidence
Context

Omada Health CFO Gracey Craig sold 2,083 shares on 2026-06-24 under a pre-arranged 10b5-1 plan, disclosing $39,601.58 proceeds.

Expected impact

Low likelihood of a sustained price move; any near-term reaction is likely muted and quickly absorbed.

Evidence & confidence

Form 4 is a primary disclosure, but the transaction is explicitly under a pre-arranged 10b5-1 plan and the dollar amount is modest relative to typical market moves.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 sale, the disclosure may be mechanically scheduled rather than information-bearing; traders may discount it entirely.

Key entities

  • Omada Health, Inc.

    Company whose CFO insider sale is disclosed on Form 4.

  • Gracey Craig

    Chief Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.